论文信息 - CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial - 字舞流文

CD20-Tcb (RG6026), a Novel "2:1" Format T-Cell-Engaging Bispecific Antibody, Induces Complete Remissions in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Phase I First in Human Trial

G. Salles | M. Bacac | C. Carlo-Stella | M. Hutchings | P. N. Morcos | C. Ferlini | M. Dickinson | F. Morschhauser | F. Offner | A. Sureda | T. Moore | N. Dimier | G. Iacoboni | M. Weisser | D. Thomas | Joaquín Martínez López | Betsy Quackenbush | A. Broeske | G. Iacoboni